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Moreover, the adverse effect of PPM on pul-
monary arterial pressure may in large part
occur in the long term. Thus the early post-
operative pulmonary arterial pressure is ob-
viously not an appropriate and reliable end
point for adequate assessment of the effects
of PPM. As opposed to the results of this
study, three recent previous studies have re-
ported that PPM is associated with a higher
incidence of persistent pulmonary hyperten-
sion after mitral valve replacement.2-4
The number of patients is far too small
and the follow-up too short to draw any
meaningful conclusion with regard to the
impact of PPM on operative and late mortal-
ities, on the persistence of pulmonary hyper-
tension, or on any other clinical outcomes.
Importantly, there is a major discrepancy
between the data reported in this small series
of patients with very short follow-up and the
data reported by two independent groups of
investigators in much larger series of pa-
tients (.800) with more than 10 years of
follow-up.3,4 These larger studies concluded
that mitral PPM, and especially severe PPM,
is an independent predictor of the persis-
tence of pulmonary hypertension, the occur-
rence of congestive heart failure, and late
mortality.
In light of the important limitations of
this study and of the results of previous stud-
ies,2-4 the results and conclusions of the
article of Totaro and Argano1 cannot be ac-
cepted at face value. We believe that among
several prosthesis models that are equivalent
in terms of durability and thromboresistance
the surgeon should logically select the one
with the largest possible EOA in a given an-
nulus size to minimize the risk of PPM and
associated complications after mitral valve
replacement.
Philippe Pibarot, DVM, PhD, FACC, FAHA
Julien Magne, MSc
Jean G. Dumesnil, MD, FRCPC, FACC
Laval Hospital Research Center
Que´bec Heart Institute
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Letters to the EditorReply to the Editor:
We thank Pibarot and coauthors for their
comments regarding our article.1 It is surely
a privilege that such distinguished colleagues
take an interest in our study. Nevertheless, we
found some of the comments inappropriate.
First, as far as the title was concerned, it
was obviously provocative and was chosen
just to underline an important matter related
to this issue. As Pibarot and coauthors
stressed in their comment, patient–prosthe-
sis mismatch (PPM) is a hemodynamic phe-
nomenon and therefore should be diagnosed
on the basis of hemodynamic parameters
related to a specific patient. This is the key
point related to PPM after mitral valve
replacement. In other words, to evaluate
clearly the impact of PPM on functional
and clinical outcomes, we have to be sure
that we are comparing patients with PPM
to patients without PPM.
As we clearly stated, this was the main
objective of our study, which was indeed fo-
cused on the identification of patients with
real PPM and on the evaluation of accuracy
of prediction and diagnosis of PPM with
data not obtained in vivo postoperatively
and therefore not related to a specific patient.
In their comments, Pibarot and coauthors
express serious concerns about the validity
of our Doppler echocardiographic data,
especially those related to effective orifice
area (EOA). We would stress that the meth-
odology we used (continuity equation
method) was validated for assessing mitralThe Journal of Thoracic and Cardiovascuvalve bioprosthesis by their own group2;
they also confirmed the good correlation be-
tween the mean in vitro and in vivo areas for
mitral prostheses. In our hands in vivo post-
operative measured EOA was indeed larger
than the EOA measured in vitro by the
manufacturer. We stressed such interesting
results in our discussion, and we also stressed
that these findings were surely unexpected on
the basis of what has clearly been demon-
strated for aortic prostheses. We do believe,
however, that our results deserve a further
analysis rather than mere criticism. It is nota-
ble that, despite few data on postoperative
hemodynamic performance after mitral valve
replacement being available, Firstenberg and
colleagues3 in 2001 reported echocardio-
graphic data consistent with our findings.
They specifically evaluated postoperative in
vivo hemodynamic performances of the
mitral Carpentier Edwards Perimount valve,
and the postoperative in vivo EOAs they
reported were consistent with our data. We
do stress that they also reported a discrete
variability (expressed in terms of SD), once
more similar to our own findings. We are still
collecting and analyzing our data for better
evaluation of the reason for such variability,
but we do believe that it is related to the fact
that the postoperative prosthetic valve in
vivo EOA depends on other physiopatho-
logic parameters than simple prosthesis
size. Different sensitivities of mitral valve he-
modynamics to chronotropic conditions,
which may vary extensively from one patient
to another was furthermore previously noted
by Pibarot and Dumesnil4 themselves in their
Journal editorial of June 2007. Further
studies addressing postoperative in vivo
hemodynamic parameters could be more
helpful in better understanding such variabil-
ity, rather than criticizing our results and
doubting their validity. In contrast to what
they stated in their comments, we did not
mention at all the ‘‘the complete absence of
correlation between the EOA and the trans-
prosthetic gradient’’ (which was, however,
previously shown by Firstenberg and co-
workers3), but rather the absence of correla-
tion between increased prosthesis size and
improved postoperative hemodynamic per-
formance. A similar concept was also previ-
ously presented by Badano and associates5
and therefore is not a unique finding of our
study.
We do not agree at all with Pibarot and
coauthors’ concerns about the ‘‘large pro-
portion of the patients included in this serieslar Surgery c Volume 135, Number 2 465
Thoracic epidural anesthesia
and atrial fibrillation after
coronary bypass grafting
To the Editor:
I read with great interest the recent article by
Dr Bakhtiary and colleagues1 detailing the
protective effect of high thoracic epidural
anesthesia against atrial fibrillation after
off-pump coronary bypass grafting. The
following clinical questions arise as a result
of this fascinating study:
1. Why was the placement of the
thoracic epidural catheters the day
before the operation?
2. Were there any thoracic epidural
placements complicated by signifi-
cant puncture-site bleeding? What
was the protocol for managing this
uncommon but important event?
Was another epidural space selected?
3. How was the epidural catheter tested
to ensure effective bilateral thoracic
anesthesia?
4. What was the management of postop-
erative b-blockade? Was b-blocker
withdrawal a possible confounder in
this study?
5. Is there any explanation for the
observation that women were more
likely to experience nausea and
vomiting in the intervention group?
6. What was the power calculation for
this study based on the existing liter-
ature? What is the probability of
a type I error, a type II error, or both?
Letters to the Editor[who] were misclassified with respect to the
presence or absence of PPM.’’ Misclassifi-
cation is definitively more frequent when
the classification is based on fixed data,
either from in vitro study or previously pub-
lished studies, and not when the classifica-
tion is based on real in vivo data that
reflect the hemodynamic condition of a spe-
cific patient. The question of why some pa-
tients with the same prosthesis size had such
different postoperative EOAs is surely mat-
ter for further discussion and evaluation, but
postoperative in vivo EOA must anyway be
considered the criterion standard for PPM
identification and cannot be considered
simply misleading just because different
patients have different EOAs.
The final two comments of Pibarot and
coauthors are all related to the clinical effect
of PPM. With respect to the effect of PPM
on pulmonary arterial pressure, Pibarot and
coauthors simply underlined what we had
already stated in our Discussion section.
Furthermore, among three recent studies
quoted by Pibarot and coauthors, the one
from Li and colleagues6 was also a key ref-
erence in our study, and the two from Magne
and coauthors7 and Lam and coworkers8
were published well after we sent our article
for consideration for publication in the
Journal (February 2007, as clearly reported
on the first page1).
With respect to clinical impact of PPM in
terms of operative and late mortalities, we
also clearly stated in the Discussion section
that our study could not be elucidative be-
cause only 8 patients had PPM. Clinical rel-
evance of PPM has to be better elucidated
and surely represents an important matter.
We would like to stress, however, that
once more the evidence must come from
a complete evaluation and analysis of differ-
ent experiences published in the literature.
Recent experiences quoted by Pibarot and
coauthors7,8 clearly identify PPM as risk
factor for poor outcome. Previous experi-
ence from Lorusso and associates9 and
Ruel and coworkers,10 however, did not
confirm different outcome in patients re-
ceiving small prostheses. Because Lam
and coworkers’ definition of patients with
PPM was not based on postoperative in
vivo data,8 patients classified as having
PPM should mainly be patients receiving
small prostheses. These data are therefore
in contrast and deserve further evaluation
and further studies. In conclusion, in our
opinion only a multicenter, prospective466 The Journal of Thoracic and Cardiostudy that is based on in vivo postoperative
evaluation of PPM could reach a better level
of evidence regarding the exact definition of
PPM at the mitral level, the real incidence of
postoperative mitral PPM, and its clinical
impact. Our study was not meant to contra-
dict results from other researchers but sim-
ply to warn about the real potential for
misclassification of patients has having
PPM solely on the basis of fixed data rather
than dynamic data specific to that patient.
For the patient receiving a mitral prosthesis,
specific postoperative in vivo evaluation
should be mandatory to evaluate the real
incidence of mitral PPM.
Finally, we would respectfully underline
that the appropriate scientific controversy
should call for a different attitude and ap-
proach to other investigators simply driven
by the same enthusiasm for proven data
about a scientific aspect whose explanation,
unless proven, is usually not in the hands of
a unique group of investigators.
Pasquale Totaro, MDa
Vincenzo Argano, MDb
Cardiac Surgery Divisiona
Civic Hospital
Brescia, Italy
Department of Thoracicb
and Cardiovascular Surgery
Villa Maria Eleonora Hospital
Palermo, Italy
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